Article
The current issue of Evidence-Based Oncology™, a publication of The American Journal of Managed Care®, examines how new reimbursement models are making cancer care more patient-centered, but making those models sustainable is challenging.
Changing cancer care payment models are rewarding doctors and practices for making care more patient-centered, but the transition isn’t easy, according to the current issue of Evidence-Based Oncology™ (EBO™), a publication of The American Journal of Managed Care®. The issue can be found here.
While there have been wondrous innovations in both therapy and practice, cancer care is not yet cost-effective and affordable for everyone, writes Joseph Alvarnas, MD, editor-in-chief of EBO™ and director of Value-Based Analytics at City of Hope, in Duarte, California.
“While we understand the right sensibilities in creating a sustainable care delivery, we have not yet created the ideal model for delivering this consistently, at scale, across a nation of more than 325 million individuals,” Alvarnas writes.
Perspectives on moving to value-based models include:
About The American Journal of Managed Care®:
The American Journal of Managed Care® (AJMC®) is a peer-reviewed, MEDLINE-indexed journal that keeps readers on the forefront of health policy by publishing research relevant to industry decision makers as they work to promote the efficient delivery of high-quality care. AJMC.com is the essential website for managed care professionals, distributing industry updates daily to leading stakeholders. Other titles in the AJMC® family include The American Journal of Accountable Care®, and two evidence-based series, Evidence-Based Oncology™and Evidence-Based Diabetes Management™. These comprehensive offerings bring together stakeholder views from payers, providers, policymakers and other industry leaders in managed care. To order reprints of articles appearing in AJMC® publications, please contact Jeff Prescott at 609-716-7777, ext. 331.
Contacts:
AJMC® Media:
Theresa Burek, 609-716-7777
or
Surabhi Verma
How to Choose Between Fixed-Duration vs Continuous BTKi Therapy for CLL